May 08, 2026 10:56 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Cloud over Tamil Nadu government formation as Governor asks Vijay to prove majority | 1 Year of Operation Sindoor: PM Modi says it showed India’s firm response to terror | ‘Larger conspiracy ahead of PM Modi’s visit’: BJP on killing of Suvendu Adhikari’s aide | ‘My car was on OLX for sale’: Siliguri owner says number plate used in Suvendu aide assassination may have been cloned online | ‘Pre-planned political assassination’: BJP’s Swapan Dasgupta on Suvendu aide’s killing | BJP leader Suvendu Adhikari's personal secretary shot dead in West Bengal's Madhyamgram | Mamata Banerjee to move Supreme Court against Bengal post-poll violence, refuses to quit | Who after Mamata in Bengal? Amit Shah to meet BJP MLA-elects ahead of May 9 oath | Vijay’s TVK seeks Congress, Left support after falling short of majority in Tamil Nadu | Jolt to TMC! Supreme Court rejects plea challenging central staff deployment at Bengal counting centres
UK COVID19
Pixabay

UK testing new drug to prevent COVID-19 development after Coronavirus contraction: Reports

| @indiablooms | Dec 26, 2020, at 02:33 pm

Moscow/Sputnik: UK scientists are testing a new drug to prevent people, who have been exposed to the coronavirus, from falling ill with COVID-19, media reported.
 

According to The Guardian, the antibody therapy has been developed by the University College London Hospitals and the AstraZeneca pharmaceutical company.

“If we can prove that this treatment works and prevent people who are exposed to the virus going on to develop Covid-19, it would be an exciting addition to the arsenal of weapons being developed to fight this dreadful virus,” virologist Catherine Houlihan, who is leading the study, said, as quoted by The Guardian.

The drug will provide patients with an immediate cocktail of antibodies that may protect them from COVID-19 for 6-12 months.

The medicine may be used as an emergency treatment both to hospital inpatients and care home residents.

The therapy may be also useful for those, who had contact with COVID-19 patients, and students, who live, study and socialize in big communities.

If approved, the drug will be available for public use in March or April.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.